Similar Posts
Exelon Corporation (NASDAQ: EXC): A Leading Energy Provider in the U.S. Power Sector
Exelon Corporation (NASDAQ: EXC) is one of the largest regulated electric utilities in the United States, headquartered in Chicago, Illinois. Originally formed in 2000 through the merger of PECO Energy Company and Unicom, Exelon provides electricity and natural gas to over 10 million customers across Illinois, Pennsylvania, Maryland, Delaware, New Jersey, and Washington, D.C.
Par Pacific Holdings, Inc.: Regional Refining & Fuel Distribution
Par Pacific is a niche downstream energy company focused on geographically isolated and supply-constrained markets, where local refining and logistics assets command pricing power.
Urban Outfitters, Inc.: Lifestyle Retail Platform Driven by Differentiated Brands
Urban Outfitters is a multi-brand lifestyle retailer targeting differentiated consumer segments across apparel, accessories, and home goods, with a strong omnichannel presence.
Logitech International S.A. (NASDAQ: LOGI): Swiss tech giant, ideal long-term investment
Logitech International S.A. (NASDAQ: LOGI) (also known as Logitech) is a Swiss-based multinational company that specializes in computer peripherals and accessories. The company designs, manufactures, and markets a wide range of products including mice, keyboards, webcams, headsets, speakers, and more.
Ameresco Inc.: At the Intersection of Sustainability, Infrastructure, and Cash Flows
Ameresco, Inc. provides energy solutions in the United States, Canada and Europe. It operates through North America Regions, U.S. Federal, Renewable Fuels, Europe, and all other segments.
Is Protagonist Therapeutics Inc. (NASDAQ: PTGX) a good buy from biotechnology Industry?
Protagonist Therapeutics, Inc.(XNAS:PGTX) is a biopharmaceutical company that discovers and develops peptide based therapeutic drugs to address hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 antagonist peptide, which is currently in Phase II clinical trials for the treatment of inflammatory bowel disease (IBD); and PN-235, an interleukin-23 receptor antagonist for the treatment of both IBD and non-IBD indications. A license and collaboration agreement has been signed between the company and Janssen Biotech Inc.